BASEL, SWITZERLAND--(Marketwire - May 23, 2008) - Contribution from cost-of-goods savings exceeds expectations Speedel Holding Ltd (SWX: SPPN) today announced that it has received from Novartis the royalty report regarding SPP100/Aliskiren (Tekturna/Rasilez[1]) for the three months ending 31st March 2008. Consequently Speedel has updated its revenues and now confirms that it has earned a total of CHF 2.58 million for the first quarter of 2008 compared to management’s best estimate of CHF 2.20 million previously announced with its financial results on May 15.
